UBS Group
TLIS

UBS Group’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

UBS Group’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11
Closed -$95 – 10384
2024
Q2 		$95 Sell
11
-109
-91% -$966 ﹤0.01% 9171
2024
Q1 		$1.05K Sell
120
-7
-6% -$58 ﹤0.01% 8251
2023
Q4 		$946 Buy
127
+36
+40% +$235 ﹤0.01% 8465
2023
Q3 		$526 Buy
91
+89
+4,450% +$608 ﹤0.01% 8441
2023
Q2 		$12 Hold
2
– – ﹤0.01% 8724
2023
Q1 		$13 Sell
2
-448
-100% -$3.81K ﹤0.01% 9452
2022
Q4 		$3.04K Buy
450
+448
+22,400% +$3.93K ﹤0.01% 9580
2022
Q3 		$0 Buy
2
+1
+100% +$13 ﹤0.01% 11147
2022
Q2 		$0 Sell
1
-182
-99% -$2.88K ﹤0.01% 11159
2022
Q1 		$4K Sell
183
-316
-63% -$10.9K ﹤0.01% 9346
2021
Q4 		$30K Buy
+499
New +$37.3K ﹤0.01% 7409
2021
Q3 		– Sell
-36
Closed -$6K – 10241
2021
Q2 		$6K Sell
36
-178
-83% -$30.2K ﹤0.01% 8474
2021
Q1 		$41K Buy
+214
New +$53.4K ﹤0.01% 6752

Other funds holding TLIS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group's TLIS Position: Q3 2024 in Review

UBS Group sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 11 shares — an estimated $95 sold.

UBS Group first reported a position in TLIS in Q1 2021 and held it in 13 quarters. The position peaked at $41K in Q1 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

  • UBS Group reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
  • UBS Group sold 11 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $95.
  • UBS Group first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 13 quarters.
  • UBS Group's Talis Biomedical Corporation Common Stock position peaked at $41K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.